Capital markets·October 22, 2026 at 9:37 PM EDT·2 sources
Lycia's $318M IPO; Merck sac-TMT trial stopped early
ipo, log scale$318M
$100M$1B$10B$100B
What happened
- Lycia priced a $318 million IPO, according to BioPharma Dive.
- The upsized offering will support three protein-degrading medicines for allergic conditions and Graves’ disease.
IPO size
$318M
Why it matters
The offering provides Lycia with capital to advance a pipeline focused on allergic conditions and Graves’ disease, relevant to healthcare investors and ECM professionals.
Deal terms
ipo
Lycia
Value
$318M
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- First reported by BioPharma DiveOct 23Protein degrader specialist Lycia prices $318M IPO
- Endpoints News reportsOct 23Lycia's $318M IPO; Merck sac-TMT trial stopped early
Sources (2)
- BioPharma DiveOct 23Protein degrader specialist Lycia prices $318M IPO
- Endpoints NewsOct 23Lycia's $318M IPO; Merck sac-TMT trial stopped early
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.